What I’m trying to work out is : is IXC going to be using a unique formulation of exenatide for IIH treatment?
If not then our sale potential must surely decrease if we are just relying on orphan drug designation
Questions to ask Tom in relation to recent announcement dated 27.09.2021, page-30
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.463M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 74259 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.8¢ | 5755 | 1 |
View Market Depth
| Last trade - 10.04am 16/10/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable